US14167L1035
© BusinessWire
26.12.2025
CDNA
LISTED
NASDAQ
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants.
On December 19, 2025, as an inducement mat...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2025
CDNA
LISTED
NASDAQ
CareDx Provides Notice of Proposed Derivative Settlement
News Preview
CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing.
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
JEFFREY EDELMAN, JAYSEN
Case No. 3:25-cv-02036-TLT
STEVENSON, and CHRISTIAN JACOBSEN,
(Shareholder Derivative Action)
Derivatively on Behalf of CareD...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
CDNA
LISTED
NASDAQ
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
News Preview
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the third manuscript from Surveillance HeartCare Outcomes Registry (SHORE) in the J...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
10.11.2025
CDNA
LISTED
NASDAQ
CareDx to Participate in Upcoming Investor Conferences
News Preview
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences:
Stephen...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
07.11.2025
CDNA
LISTED
NASDAQ
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants.
On November 4, 2025, as an inducement materi...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
CDNA
LISTED
NASDAQ
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data presentations featuring CareDx technologies at American Society of...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
CDNA
LISTED
NASDAQ
CareDx Announces Third Quarter 2025 Financial Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025.
Third Quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
CDNA
LISTED
NASDAQ
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
News Preview
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, eff...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
CDNA
LISTED
NASDAQ
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure
News Preview
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the second study from Surveillance HeartCare Outcomes Registry (SHORE) in the Journ...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
CDNA
LISTED
NASDAQ
CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors
News Preview
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors.
Suresh currently serves as President and Chief Execu...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
CDNA
LISTED
NASDAQ
CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025. The Co...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
CDNA
LISTED
NASDAQ
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new innovations and products that will be featured at The American Society f...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
02.09.2025
CDNA
LISTED
NASDAQ
CareDx Issues Comment Letter on Draft LCD Policy
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has submitted its comment letter in response to the draft Local Cove...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
CDNA
LISTED
NASDAQ
CareDx to Participate in Wells Fargo Healthcare Conference
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in a fireside chat at the Wells Fargo Healthcar...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
CDNA
LISTED
NASDAQ
CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress
News Preview
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the presentation of several high-impact studies and digital health innovatio...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
CDNA
LISTED
NASDAQ
CareDx to Report Second Quarter 2025 Financial Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Compa...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
CDNA
LISTED
NASDAQ
CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced the release of a proposed draft Local Coverage Determination (LCD) related to mole...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
CDNA
LISTED
NASDAQ
CareDx Announces Repurchase of 5% of Outstanding Shares
News Preview
CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock repr...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
CDNA
LISTED
NASDAQ
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
News Preview
Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.
What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certa...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
CDNA
LISTED
NASDAQ
CareDx to Participate in Upcoming Investor Conferences
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences.
Craig-...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
CDNA
LISTED
NASDAQ
CareDx Reports First Quarter 2025 Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the first quarter ended March 31, 2025.
First Quarter Financial Highlights
Reported first quarter revenue of $84.7 million, increased 18% year-over-year
Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100,...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
CDNA
LISTED
NASDAQ
CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators, presented new scientific evi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
CDNA
LISTED
NASDAQ
CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators from leading transplant cente...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
CDNA
LISTED
NASDAQ
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ (“CareDx” or the “Company”)— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennife...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
CDNA
LISTED
NASDAQ
CareDx to Report First Quarter 2025 Financial Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Compan...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
CDNA
LISTED
NASDAQ
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
CDNA
LISTED
NASDAQ
CareDx Launches Two Expanded Indications for AlloSure Testing Services
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
CDNA
LISTED
NASDAQ
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
CDNA
LISTED
NASDAQ
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024.
Fourth Quarter Financial Highlights
Revenue of $86.6 million, increased 32% year-over-year
Testing services revenue of $63.8 million, increased 37% year-over-year, and testing services volume of approximately 45,500, i...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
CDNA
LISTED
NASDAQ
CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation brought by a competitor.
The District Co...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
CDNA
LISTED
NASDAQ
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
News Preview
Johnson Fistel, LLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.
What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certai...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
CDNA
LISTED
NASDAQ
CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings published in Transplant International1 that show the performance of...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
CDNA
LISTED
NASDAQ
CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new AlloHeme data presented at the 2025 Tandem Meetings, Transplantation &am...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
CDNA
LISTED
NASDAQ
CareDx to Report Fourth Quarter and Full Year 2024 Financial Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, Februar...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
CDNA
LISTED
NASDAQ
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Preliminary Fourth Quarter 2024 Financial Results
Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year.
Testi...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
CDNA
LISTED
NASDAQ
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan He...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
CDNA
LISTED
NASDAQ
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysi...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
CDNA
LISTED
NASDAQ
CareDx to Participate in Upcoming Investor Conferences
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences.
Jeffe...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
CDNA
LISTED
NASDAQ
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance
News Preview
CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights
Total revenue of $82.9 million increased 23% year-over-year
Testing Services volume of 44,600 tests increased 16% year-over-year
GAAP net loss of $7.4 million, non-GAAP net income of $8.0 mi...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
CDNA
LISTED
NASDAQ
CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of healthcare solutions for transplant patients and caregivers, and Dovetail Genomics, a leader in the field of genomic solutions — today announced a strategic partnership to drive the next wave...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
CDNA
LISTED
NASDAQ
CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data and product enhancements being presented at the 50th annual meeting...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
CDNA
LISTED
NASDAQ
CareDx Reports Preliminary Financial Results for Third Quarter 2024
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024....
Themefolio
Profiler
Peergroup
© BusinessWire
11.10.2024
CDNA
LISTED
NASDAQ
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company’s newly...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
CDNA
LISTED
NASDAQ
CareDx Appoints Jing Huang Chief Data and AI Officer
News Preview
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
CDNA
LISTED
NASDAQ
CareDx to Host Investor Day on October 15, 2024
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the Company will be hosting an Investor Day on October 15, 2024, in New York...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
CDNA
LISTED
NASDAQ
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Department of Justice (DOJ) has concluded its investigation into Ca...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
CDNA
LISTED
NASDAQ
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 sha...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
CDNA
LISTED
NASDAQ
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2024
CDNA
LISTED
NASDAQ
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strate...
Themefolio
Profiler
Peergroup
© BusinessWire
16.08.2024
CDNA
LISTED
NASDAQ
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
News Preview
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ – today announced that the Centers for Medicare and Medicaid Services (CMS) has announced its plan to retire a draft LCD that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection. Combined with the February 2024 removal of restrictive language...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
